Gyroscope Capital Management Group LLC continued to hold its position in Amgen, Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,450 shares of the medical research company’s stock at the end of the 2nd quarter. Gyroscope Capital Management Group LLC’s holdings in Amgen were worth $422,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in AMGN. PGGM Investments grew its position in shares of Amgen by 2.3% in the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock valued at $115,555,000 after purchasing an additional 15,059 shares in the last quarter. Shelton Capital Management grew its position in shares of Amgen by 82.7% in the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock valued at $17,883,000 after purchasing an additional 49,354 shares in the last quarter. Greylin Investment Mangement Inc. grew its position in shares of Amgen by 466.9% in the second quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock valued at $2,416,000 after purchasing an additional 11,555 shares in the last quarter. Kelman Lazarov Inc. boosted its stake in Amgen by 8.2% during the second quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock valued at $272,000 after buying an additional 120 shares during the period. Finally, Osborne Partners Capital Management LLC boosted its stake in Amgen by 0.5% during the second quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock valued at $2,932,000 after buying an additional 91 shares during the period. 78.62% of the stock is owned by institutional investors and hedge funds.

In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,050 shares of company stock worth $1,239,673. 0.19% of the stock is owned by company insiders.

Amgen, Inc. (NASDAQ:AMGN) opened at $176.83 on Tuesday. Amgen, Inc. has a twelve month low of $142.79 and a twelve month high of $191.10. The stock has a market capitalization of $127,331.98, a PE ratio of 13.94, a P/E/G ratio of 2.54 and a beta of 1.36. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the previous year, the business earned $3.02 EPS. Amgen’s revenue was down .7% compared to the same quarter last year. equities analysts forecast that Amgen, Inc. will post 12.66 earnings per share for the current year.

Amgen declared that its board has authorized a share repurchase program on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 8th. Investors of record on Friday, November 17th were issued a dividend of $1.15 per share. The ex-dividend date was Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a yield of 2.60%. Amgen’s dividend payout ratio is presently 41.63%.

AMGN has been the subject of several research analyst reports. Mizuho reissued a “buy” rating and set a $198.00 price objective (up previously from $183.00) on shares of Amgen in a research note on Thursday, September 28th. BMO Capital Markets reissued a “hold” rating and set a $198.00 price objective on shares of Amgen in a research note on Friday, October 20th. Jefferies Group reissued a “buy” rating and set a $200.00 price objective on shares of Amgen in a research note on Monday, September 25th. Royal Bank of Canada began coverage on Amgen in a research note on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price objective for the company. Finally, Barclays lifted their price target on Amgen from $180.00 to $190.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. Amgen currently has an average rating of “Hold” and a consensus price target of $190.22.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/12/gyroscope-capital-management-group-llc-has-422000-position-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.